Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 15/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267822 | 0.92 | ABCB1 (0.49) | ABCB1ACE2TSHRRAB9AHSD17B10 | |
| SCHEMBL268163 | 0.85 | ABCB1 (0.41) | ABCB1ACE2TSHRRAB9AHSD17B10 | |
| SCHEMBL268164 | 0.85 | ABCB1 (0.41) | ABCB1ACE2TSHRRAB9AHSD17B10 | |
| SCHEMBL266550 | 0.82 | SLC34A2 (0.45) | ABCB1 | |
| SCHEMBL274542 | 0.82 | SLC34A2 (0.45) | ABCB1 | |
| SCHEMBL266551 | 0.82 | SLC34A2 (0.45) | ABCB1 | |
| SCHEMBL266570 | 0.81 | NPC1 (0.39) | TSHRRAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL269615 | 0.79 | ABCB1 (0.40) | ABCB1SMN1; SMN2MAPK1 | |
| SCHEMBL269616 | 0.79 | ABCB1 (0.40) | ABCB1SMN1; SMN2MAPK1 | |
| SCHEMBL267909 | 0.76 | SLC34A2 (0.43) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-28 | — | — | US | disclosed |
| EP-1614676-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217426-A1 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | SLC10A6, SLC7A1, SLC10A1 | ABCB1 181/4885ACE2 2265/4885TSHR 729/4885 |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | ABCB1 260/4885ACE2 2795/4885TSHR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.